Comparative Pharmacology
Head-to-head clinical analysis: QUESTRAN versus QUESTRAN LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUESTRAN versus QUESTRAN LIGHT.
QUESTRAN vs QUESTRAN LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing their enterohepatic reabsorption and increasing hepatic LDL receptor activity and cholesterol catabolism.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver.
Questran (cholestyramine) is administered orally. The typical adult dose is 4 grams (one packet or one level scoop) once or twice daily, with a maximum of 24 grams per day. The powder should be mixed with at least 120 mL of fluid (e.g., water, juice).
4 grams (one packet or one level scoop) orally once or twice daily, with a maximum of 24 grams per day. Dose may be increased by 4 grams daily at weekly intervals as needed.
None Documented
None Documented
Not applicable; the drug is not absorbed and does not have a systemic half-life. Clinical effect persists as long as the resin remains in the gut (approximately 6-8 hours per dose).
Not applicable; cholesteryamine resin is not absorbed systemically; half-life refers to GI transit time (~2-4 hours).
Cholestyramine is not absorbed from the gastrointestinal tract; therefore, it is excreted entirely in the feces as the intact resin, with no renal or biliary excretion.
Primarily fecal (as resin-bound bile acids); less than 0.05% renally excreted unchanged.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant